Overview
Updated 14 Jul 2026
Jedd Wolchok, MD, is Sandra and Edward Meyer Director, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. The public record shows 1,448 publications with 208,418 citations (h-index 176), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 7 companies, 7 NIH-funded awards (2009–2026).
- Most recent indexed publication: 2026 · The Journal of experimental medicine
- Top research focus: Cancer Immunotherapy and Biomarkers
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 60 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 551.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Sponsor: Memorial Sloan Kettering Cancer Center
InvestigatorPhase 1/PHASE2CompletedNCT02281409 - A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Sponsor: Ludwig Institute for Cancer Research
InvestigatorPhase 1CompletedNCT01975831 - Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Sponsor: Ludwig Institute for Cancer Research
InvestigatorPhase 1/PHASE2WithdrawnNCT01689870
Industry payments
Updated 14 Jul 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Astellas Pharma US IncProgram year20253 payments
- TAIHO ONCOLOGY, INC.Program year20251 payment
NIH funding
Updated 14 Jul 2026
7 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Identifying targets to mitigate immunotherapy-associated immune-related adverse events
Weill Medical Coll of Cornell Univ
FY2026$703,423R01CA306020 - Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies
Weill Medical Coll of Cornell Univ
FY2026$685,737R01CA297338 - Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies
Weill Medical Coll of Cornell Univ
FY2025$702,748R01CA297338
Congress activity
Updated 14 Jul 2026
228 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 5624: Clinical strategies to enhance the efficacy of tumor-infiltrating lymphocyte (TIL) therapy using preclinical models
AACR Annual Meeting
AACR2026Co-author - Abstract 6537: Tumor IDO1 drives resistance to adoptive cell transfer by suppressing T cell recruitment and effector function
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.
The Journal of experimental medicine
2026 - Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery.
Journal of clinical oncology
2026
Most-cited worksby citation count (OpenAlex)
- 01Improved Survival with Ipilimumab in Patients with Metastatic Melanoma15,164 citations2010
- 02Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma8,158 citations2015
- 03
- 04Cancer immunotherapy using checkpoint blockade6,751 citations2018
- 05Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma5,396 citations2017
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
1305 York Ave., 12th Floor, New York, NY 10065
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗ - Board Certified
Medical Oncology (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connection.asco.org ↗
- Member
Scientific Advisory Council, Cancer Research Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerresearch.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.weill.cornell.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Secondary affiliationsappointments beyond the home institution
- Memorial Sloan Kettering Cancer Center
formerly Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation and Chief of Immuno-Oncology Service, prior to 2022 move to Weill Cornell
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗ - Ludwig Institute for Cancer Research
Board of Directors member; Co-Director, Ludwig Collaborative Laboratory at Weill Cornell Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ludwigcancerresearch.org ↗ - NewYork-Presbyterian Hospital
Cutaneous Oncology and Melanoma Program, attending physician
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.nyp.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗
- Feature profile
The Cancer Letter, "Weill Cornell's path to NCI designation runs through Brooklyn and Queens"
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/jedd-wolchok-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jedd-wolchok-a8665b6
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/lab/Jedd-D-Wolchok-Lab
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/weillcornellmedicine_dr-jedd-wolchok-appointed-meyer-director-activity-6958402433865678849-DPV8
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/how-melanoma-met-its-match-cancer-immunotherapy/id1789801996
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - Spotify
open.spotify.com/episode/4Xq1LBDqMikTOJ3B5wKSPe
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ronald Crystal, MD
Weill Cornell Medicine
- 1,093
- publications
- 155
- h-index
- 43
- trials
Myles Wolf, MD
Weill Cornell Medicine
- 369
- publications
- 93
- h-index
- 4
- trials
Roy Gulick, MD, MPH
Weill Cornell Medicine
- 282
- publications
- 63
- h-index
- 7
- trials
Parag Goyal, MD
Weill Cornell Medicine
- 453
- publications
- 44
- h-index
- 10
- trials